Effective achievement of hemoglobin stability with once-monthly C.E.R.A. in peritoneal dialysis patients: A prospective study

Clinical Drug Investigation

Volumn 33, Issue 10, 2013, Pages 699-706

  Koch, Michael ^a   Treiber, Wolfgang ^b   Fliser, Danilo ^c  

^a Nephrology Center   (Germany)

^b Renal and Hypertension Center   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; HEMOGLOBIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; VITAL SIGN;

ADULT; AGED; AGED, 80 AND OVER; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECEPTORS, ERYTHROPOIETIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885158095     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0091-z     Document Type: Article

References (39)

1. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20:1501-10.
2. Ossareh S, Roozbeh J, Krishnan M, Liakopoulos V, Bargman JM, Oreopoulos DG. Fatigue in chronic dialysis patients. Int Urol Nephrol. 2003;35:535-41.
3. García-López E, Carrero JJ, Suliman ME, Lindholm B, Stenvinkel P. Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis. Perit Dial Int. 2007;27(Suppl 2):S205-9.
4. Fortes PC, de Moraes TP, Mendes JG, Stinghen AE, Ribeiro SC, Pecoits-Filho R. Insulin resistance and glucose homeostasis in peritoneal dialysis. Perit Dial Int. 2009;29(Suppl 2):S145-8.
5. Li S, Foley RN, Collins AJ. Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int. 2004;65:1864-9.
6. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004;19:121-32.
7. Valderrábano F. Quality of life benefits of early anaemia treatment. Nephrol Dial Transplant. 2000;15(Suppl 3):23-8.
8. Locatelli F, Covic A, Eckardt KU, Wiecek A, Vanholder R, ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2009;24:348-54.
9. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl. 2012;2:279-335.
10. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999;10:2392-5.
11. Halstenson CE, Macres M, Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin beta. Clin Pharmacol Ther. 1991;50:702-12.
12. Suzuki H, Inoue T, Watanabe Y, et al. Testing a single monthly dose of darbepoetin alpha to maintain hemoglobin levels in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial. 2011;27:60-4.
13. Theodoridis M, Passadakis P, Kriki P, et al. Efficient monthly subcutaneous administration of darbepoetin in stable CAPD patients. Perit Dial Int. 2005;25:564-9.
14. Hiramatsu M, Kubota M, Iwaksi M, Panagoutsos S, Yannatos E, Kantartzi K, KRN321 A09 Study Group. Darbepoetin alfa (KRN321) administered intravenously once monthly maintains hemoglobin levels in peritoneal dialysis patients. Ther Apher Dial. 2008;12:19-27.
15. Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2006;1:1211-5.
16. Locatelli F, Villa G, de Francisco ALM, on behalf of the BA16286 Study Investigators, et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin. 2007;23:969-79.
17. Levin NW, Fishbane S, Cañedo FV, MAXIMA Study Investigators, et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet. 2007;370:1415-21.
18. Sulowicz W, Locatelli F, Ryckelynck JP, PROTOS Study Investigators, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007;2:637-46.
19. Fliser D, Kleophas W, Dellanna F, et al. Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study. Curr Med Res Opin. 2010;26:1083-9.
20. Weinreich T, Leistikow F, Hartmann HG, Vollgraf G, Dellanna F, the SESAM Study Group. Monthly continuous erythropoietin receptor activator treatment maintains stable hemoglobin levels in routine clinical management of hemodialysis patients. Hemodial Int. 2012;16:11-9.
21. Stegmayr BG. Better response to s.c. erythropoietin in CAPD than HD patients. Scand J Urol Nephrol. 1997;31:183-7.
22. Sieniawska M, Roszkowska-Blaim M. Recombinant human erythropoietin dosage in children undergoing hemodialysis and continuous ambulatory peritoneal dialysis. Pediatr Nephrol. 1997;11:628-30.
23. Snyder JJ, Foley RN, Gilbertson DT, Vonesh EF, Collins AJ. Hemoglobin levels and erythropoietin doses in hemodialysis and peritoneal dialysis patients in the United States. J Am Soc Nephrol. 2004;15:174-9.
24. Coronel F, Herrero JA, Montenegro J, et al. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis. J Nephrol. 2003;16:697-702.
25. Richardson D, Ford D, Gilg J, Williams A. UK Renal Registry 12th Annual Report (December 2009): chapter 9: anaemia variables in UK adult dialysis patients in 2008: national and centre-specific analyses. Nephrol Clin Pract. 2010;115(Suppl 1):c153-86.
26. Soffritti S, Russo G, Cantelli S, Gilli G, Catizone L. Maintaining over time clinical performance targets on anaemia correction in unselected population on chronic dialysis at 20 Italian centres. Data from a retrospective study for a clinical audit. BMC Nephrol. 2009;10:33.
27. St Peter WL, Obrador GT, Roberts TL, Collins AJ. Trends in intravenous iron use among dialysis patients in the United States (1994-2002). Am J Kidney Dis. 2005;46:650-60.
28. Locatelli F, Del Vecchio L, Andrulli S. The modality of dialysis treatment: does it influence the response to erythropoietin treatment? Nephrol Dial Transplant. 2001;16:1971-4.
29. House AA, Pham B, Pagé DE. Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities. Nephrol Dial Transplant. 1998;13:1763-9.
30. Locatelli F, Aljama P, Bárány P, European Best Practice Guidelines Working Group, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(Suppl 2):ii1-47.
31. Levey AS, Coresh J, Greene T, et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53:766-72.
32. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68:1337-43.
33. van der Putten K, van der Baan FH, Schellekens H, Gaillard CA. Hemoglobin variability in patients with chronic kidney disease in the Netherlands. Int J Artif Organs. 2009;32:787-93.
34. Dellanna F, Winkler RE, Bozkurt F, MIRACEL Study Group, et al. Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study. Int J Clin Pract. 2011;65:64-72.
35. Mann JF, de Francisco A, Nassar G, Canaud B. Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease. Clin Nephrol. 2011;76:9-15.
36. Selby NM, Fonseca SA, Fluck RJ, Taal MW. Hemoglobin variability with epoetin beta and continuous erythropoiesis receptor activator in patients on peritoneal dialysis. Perit Dial Int. 2012;32:177-82.
37. Roche A, Macdougall IC, Walker RG. Hemoglobin fluctuations in patients on haemodialysis treated with ESAs: clinical observations from two centres. Curr Med Res Opin. 2009;25:2971-6.
38. Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol. 2008;3:133-8.
39. Carrera F, Lok CE, de Francisco A, et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant. 2010;25:4009-17.